Skip to content
Screener

Shares (Diluted) at other companies

Gilead Sciences logo
Gilead SciencesGILD
1.2B-1.0%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
68M+7.8%
LQD
Liquidia CorporationLQDA
101.1M+18.7%
ALN
Alnylam PharmaceuticalsALNY
138.3M+5.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
194.8M+2.4%
Arrowhead Research logo
Arrowhead ResearchARWR
142.4M+5.9%

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Numerator:
Net loss$(67,227)$(5,861)$(857,382)$(20,538)
Denominator:
Weighted-average shares of common stock outstanding62,837,77149,726,82360,653,88449,310,255
Add: weighted average of common stock to be issued upon exercise of pre-funded warrants536,412471,213
Weighted average shares of common stock used to compute net loss per share, basic and diluted63,374,18349,726,82361,125,09749,310,255
Net loss per share, basic and diluted$(1.06)$(0.12)$(14.03)$(0.42)

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s shares (diluted)?
Mirum Pharmaceuticals, Inc. (MIRM) reported shares (diluted) of 63.4M in Q2 2026.
How has Mirum Pharmaceuticals, Inc.'s shares (diluted) changed year-over-year?
Mirum Pharmaceuticals, Inc.'s shares (diluted) increased by 27.4% year-over-year, from 49.7M to 63.4M.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s shares (diluted) has grown at a 14.2% compound annual growth rate (CAGR), from 121.1M to 205.8M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Mirum Pharmaceuticals, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude